Premium
Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men
Author(s) -
Kusumoto Masaaki,
Ueno Kazuyuki,
Oda Ayumi,
Takeda Kazuya,
Mashimo Kohji,
Takaya Kameda,
Fujimura Yasuo,
Nishihori Takako,
Tanaka Kazuhiko
Publication year - 2001
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1067/mcp.2001.113182
Subject(s) - fluvoxamine , mexiletine , pharmacokinetics , pharmacology , cyp2d6 , drug interaction , crossover study , cyp1a2 , medicine , reuptake inhibitor , oral administration , cytochrome p450 , chemistry , anesthesia , serotonin , fluoxetine , metabolism , receptor , alternative medicine , pathology , placebo
Background and Objectives Fluvoxamine, a selective serotonin reuptake inhibitor, is known to inhibit several hepatic cytochrome P450 (CYP) isozymes, in particular CYP1A2. Mexiletine is mainly catalyzed by CYP2D6 and partially catalyzed by CYP1A2. Our objective was to study the potential pharmacokinetic interaction between fluvoxamine and mexiletine. Methods A randomized crossover design with two phases was used. A 7‐day washout period separated the two treatment conditions. In the one phase, 6 healthy Japanese men received an oral dose of 200 mg of mexiletine alone (study 1); in the other phase, the men received fluvoxamine (50 mg twice a day) for 7 days, and on the eighth day they received oral mexiletine (200 mg) and fluvoxamine concomitantly (study 2). The concentrations of mexiletine were measured with HPLC. Results The area under the concentration‐time curve and serum peak concentration of mexiletine in study 2 were significantly increased compared with those in study 1 (10.4 ± 4.85 versus 6.70 ± 3.21 μg · h/mL, P = .006 and 0.623 ± 0.133 versus 0.536 ± 0.164 μg/mL, P = .008, respectively). Conclusion The effect of fluvoxamine on the mexiletine disposition is comparatively large, and when mexiletine and fluvoxamine are coadministered careful monitoring of mexiletine is needed. Clinical Pharmacology & Therapeutics (2001) 69 , 104–107; doi: 10.1067/mcp.2001.113182